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Main text
Human  induced  pluripotent  stem  cells  (hIPSCs)  represent  a  unique  opportunity  for 
regenerative medicine since they offer the prospect of generating unlimited quantities of 
cells  for  autologous  transplantation  as  a  novel  treatment  for  a  broad  range  of 
disorders1,2,3,4. However, the use of hIPSCs in the context of genetically inherited human 
disease will  require correction of disease-causing mutations in a manner that is fully 
compatible  with  clinical  applications3,5.  The  methods  currently  available,  such  as 
homologous  recombination,  lack  the  necessary  efficiency  and  also  leave  residual 
sequences in the targeted genome6. Therefore, the development of new approaches to 
edit  the  mammalian  genome  is  a  prerequisite  to  delivering  the  clinical  promise  of 
hIPSCs.  Here,  we  show  that  a  combination  of  zinc  finger  nucleases  (ZFNs)7 and 
piggyBac8,9 technology in hIPSCs can achieve bi-allelic correction of a point mutation 
(Glu342Lys) in the α1-antitrypsin (A1AT, also called SERPINA1) gene that is responsible 
for α1-antitrypsin deficiency (A1ATD). Genetic correction of hIPSCs restored the structure 
and  function  of  A1AT  in  subsequently  derived  liver  cells  in  vitro and  in  vivo.  This 
approach is significantly more efficient than any other gene targeting technology that is 
currently available and crucially prevents contamination of the host genome with residual 
non-human sequences. Our results provide the first proof of principle for the potential of 
combining  hIPSCs  with  genetic  correction  to  generate  clinically  relevant  cells  for 
autologous cell-based therapies.
Currently available methods for gene targeting rely on positive selection to isolate rare 
clones  that  have  undergone  homologous  recombination.  To  remove  the  unwanted 
selection cassettes, Cre/loxP or Flp/FRT recombination systems are used, which leave 
behind single loxP or FRT sites10,11. These small ectopic sequences have the potential to 
interfere with transcriptional regulatory elements of surrounding genes, most of which 
are  not  fully  characterized in  the human genome.  An alternative  method to  remove 
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selection cassettes is to convert them into transposons. The most suitable transposon for 
this  purpose  is  piggyBac,  a  moth-derived  DNA  transposon,  which  can  transpose 
efficiently  in  mammalian  cells  including  human  embryonic  stem  cells  (hESCs)9,12.  A 
remarkable feature of this mobile element is seamless excision, which enables removal 
of  transgenes  flanked  by  piggyBac inverted  repeats  without  leaving  any  residual 
sequences9,13. 
To explore the use of piggyBac for the correction of point mutations, we designed a 
vector  to  correct  a  missense  mutation  (G290T)  in  the  Tyr gene  in  mouse  induced 
pluripotent stem cells (mIPSCs) isolated from fibroblasts of the C57Bl6-Tyrc-Brd  strain14. 
This  genetic  defect  results  in  an  albino  phenotype  that  can  be  monitored  through 
observation of the coat color. A targeting vector was constructed, carrying a wild-type 
290G sequence and a PGK-pu∆tk cassette flanked by piggyBac inverted repeats into the 
TTAA site, 269 bp downstream of the mutation (Fig. 1a). Targeted clones were identified 
and verified by Southern blot and PCR analyses (Fig. 1b, c). All targeted clones showed 
correction  of  the  point  mutation.  The  selection  cassette  was  then  excised  from the 
mIPSCs genome by transient expression of the piggyBac transposase followed by FIAU 
selection. Transposon excision was verified by Southern blot and PCR analyses (Fig. 1b, 
c).  The  correction  of  the  G290T  mutation  and  seamless  piggyBac excision  were 
confirmed by sequence analyses (Fig. 1d, e). Two introduced silent mutations observed 
following targeting and excision confirmed that the T290G substitution was mediated by 
gene correction, not by spontaneous reversion (Fig. 1e). The function of the reverted 
allele was tested by injecting the corrected mIPSCs into albino mouse blastocysts. The 
resulting chimeric mice displayed a black coat color, indicating phenotypic correction of 
the albino mutation (Fig. 1f). These results collectively demonstrate that the  piggyBac 
transposon can be used as a versatile tool for highly precise modification (e.g. correction 
or mutation) of the mammalian genome at a single base-pair level.  
We next explored whether this approach could be used to correct a mutation in 
hIPSCs derived from individuals with  α1-antitrypsin deficiency (A1ATD)15. A1ATD is an 
autosomal  recessive  disorder  found  in  1  out  of  2000  individuals  of  North  European 
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descent and represents the most common inherited metabolic disease of the liver16,17. It 
results from a single point mutation in the A1AT gene (the  Z allele; Glu342Lys) that 
causes  the  protein  to  form  ordered  polymers  within  the  endoplasmic  reticulum  of 
hepatocytes16,17.  The  resulting  inclusions  cause  cirrhosis  for  which  the  only  current 
therapy is liver transplantation. The increasing shortage of donors and harmful effects of 
immunosuppressive  treatments  impose  major  limitations  on  organ  transplantation, 
making  the  potential  of  hIPSC-based  therapy  highly  attractive.  Since  homologous 
recombination is relatively inefficient in human pluripotent stem cells6, we employed ZFN 
technology, which stimulates gene targeting in hESCs as well as hIPSCs7,10,18. ZFN pairs 
were designed to specifically cleave the site of the Z mutation (Fig. 2a-c, Supplementary 
Table 1 and Supplementary Note). A targeting vector was constructed from isogenic DNA 
with  piggyBac repeats  flanking  the  PGK-pu∆tk  cassette  (Fig.  2a).  To  minimize  the 
distance between the mutation and the piggyBac transposon, a CTG leucine codon, 10 bp 
upstream of the mutation, was altered to a TTA leucine codon, generating the TTAA 
sequence, which would be left in the genome following piggyBac excision (Fig. 2b).
Puromycin-resistant  hIPSC  colonies  obtained  after  co-electroporation  of  ZFN 
expression vectors and the targeting vector were screened for targeted clones by PCR. 
A1ATD-hIPSC lines derived from 3 different patients yielded targeted clones (Table 1a). 
Remarkably, 54% of the puromycin-resistant colonies were targeted on one allele, while 
4% were the result of simultaneous targeting of both alleles (Supplementary Fig. 1). 
To remove the piggyBac-flanked selection cassette from these modified clones, we 
transiently  transfected  2  homozygously  targeted  clones  (B-16  and  C-G4)  with  a 
hyperactive form of the  piggyBac transposase8 and subjected them to FIAU selection. 
The  genotype  of  the  resulting  FIAU-resistant  colonies  was  analyzed  by  PCR  and 
confirmed by Southern blot (Fig. 2d and Supplementary Fig. 2a). Bi-allelic excision was 
observed  in  11%  of  FIAU-resistant  colonies  (Table  1b).  Sequence  analyses  further 
demonstrated that the  Z mutation was corrected on both alleles and that transposon 
excision yielded a TTAA sequence as initially planned (Fig. 2b, e and Supplementary Fig. 
2b). To ensure that the genome modifications had not altered the pluripotency of the 
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corrected  A1ATD-hIPSCs  (c-hIPSCs),  we  confirmed  that  the  resulting  c-hIPSC  lines 
maintained the expression of pluripotency markers (OCT4, SOX2, NANOG and TRA1-60) 
for  more  than  20  passages  and  their  abilities  to  differentiate  into  cells  expressing 
markers of the three germ layers (Supplementary Fig. 3). 
Genomic instability is known to be associated with prolonged culture of hESCs19,20 
and those  arising during  genome modification  would  be  another  concern  for  clinical 
application of hIPSCs. Therefore, we analyzed the genomic integrity of the hIPSCs lines 
using array-based comparative genomic hybridization (CGH) (Supplementary Table 2a-
c). Two out of three A1ATD-hIPSC primary lines differed from the fibroblasts from which 
they were derived, showing single-copy amplifications or deletions ranging from 20 kb to 
1.3 Mb, including a gain of 20q11.21, a frequently amplified region in hESCs21,22 (see 
Supplementary Analysis and Supplementary Fig. 4 for more detail). Line A retained a 
normal genome content compared to its parental fibroblast. Reassuringly, we found that 
after  ZFN-stimulated  targeting,  four  out  of  six  homozygous  clones  had  unaltered 
genomes  compared  to  their  parental  hIPSC  lines.  Sixteen  cell  lines  with  bi-allelic 
piggyBac excision were compared with their corresponding primary hIPSCs and 12 had 
unaltered genomes. We also analyzed the hIPSC lines by high-density SNP arrays to 
check for loss of heterozygosity and found that all lines analyzed retained heterozygosity 
throughout their genome (Supplementary Fig. 5). This observation demonstrates that bi-
allelic  gene  correction  was  the  result  of  simultaneous  homologous  recombination 
followed by simultaneous excision at both alleles and that mitotic recombination was not 
involved in this process. 
To further confirm that ZFN-stimulated targeting or  piggyBac excision were not 
mutagenic at a single basepair resolution, we sequenced the exomes of the corrected B-
16-C2 line and the original parental fibroblast. Comparison of these exomes identified 29 
mutations. The genesis of these mutations was determined by analysis of the primary 
hIPSC line and the bi-allelic targeted intermediate before piggyBac excision. Twenty-four 
point mutations and one 1-bp deletion were detected in the primary hIPSC line and four 
mutations  arose  during  genetic  correction:  one  during  targeting  and  three  during 
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piggyBac excision. These mutations appeared to arise during culture since their genomic 
signatures  were  inconsistent  with  ZFN  off-target  sites  or  piggyBac integration  sites 
(Supplementary Analysis). Taken together, we conclude that the combination of ZFNs 
with piggyBac provides a new method for rapid and clean correction of a point mutation 
in hIPSCs without affecting their basic characteristics.
To  confirm  that  the  genetic  correction  of  hIPSCs  resulted  in  the  expected 
phenotypic correction, hIPSCs were differentiated in vitro into hepatocytes, the main cell 
type affected by the disease  A1ATD. Differentiation of the corrected lines occurred as 
expected; by day 3 approximately 80% of cells expressed the endoderm marker CXCR4 
and at the end of the protocol 80% of the cells expressed albumin (Supplementary Fig. 
6a-c), confirming that c-hIPSCs can differentiate into a near homogenous population of 
hepatocytes.  Remarkably,  CGH analysis  using differentiated hepatocytes  showed that 
hepatic differentiation neither increases the number of genetic abnormalities nor selects 
for cells with abnormal karyotype (Supplementary Table 2d). Furthermore, the resulting 
cells  shared key functional attributes of their  in vivo counterparts including glycogen 
storage, LDL Cholesterol  incorporation, albumin secretion and Cytochrome P450 drug 
metabolism  (Supplementary  Fig.  6d-g).  Importantly,  immunofluorescence  and  ELISA 
both confirmed the absence of mutant polymeric A1AT in c-hIPSCs-derived hepatocytes 
(Fig.  3a-c)  that  instead  efficiently  secreted  normal  endoglycosidase–H-insensitive 
monomeric A1AT (Fig. 3d). In addition, secreted A1AT displayed an enzymatic inhibitory 
activity that was comparable to that obtained from normal adult hepatocytes (Fig. 3e), 
thereby suggesting that physiological restoration of enzyme inhibitory activity could be 
achieved by use of such cells. 
Finally,  the  in  vivo function  of  corrected  hIPSCs  (B-C16-2  line)  was  assessed 
following transplantation into the liver of Alb-uPA+/+;Rag2-/-;Il2rg-/- mice via intra-splenic 
injection.  Livers  harvested  14  days  after  injection  were  colonized  by  human  cells 
identified using antibodies specific to human albumin and A1AT (Fig. 3f, g). These human 
hepatocytes were distributed throughout the liver lobes and were seen to be integrated 
into  the  existing  mouse  parenchyma  (Fig.  3f,  g).  In  addition,  human  albumin  was 
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detected in the serum of transplanted animals for at least 5 weeks (Fig. 3h), while no 
tumor formation was detected in any mice.  Therefore,  c-hIPSCs-derived hepatocytes 
were able to colonize the liver  in vivo and display functional activities characteristic of 
their human ESC-derived counterparts23.  Collectively these analyses demonstrate that 
gene editing by ZFNs together with piggyBac had not impaired the capacity of hIPSCs to 
differentiate  and  that  genetic  correction  of  the  Z mutation  resulted  in  functional 
restoration of A1AT in patient-derived cells. 
All  experimental  evidence  above  strongly  support  the  applicability  of  genetic 
correction  in  patient-specific  iPSCs  for  cell-based  therapy  of  A1ATD.  We  therefore 
repeated the genetic  correction in more clinically  relevant cells  using patient-specific 
iPSCs  reprogrammed  from  fibroblasts  with  Sendaiviral  vectors,  an  integration-free 
method (Supplementary Fig. 7a-f). One primary iPSC line with an intact genome by CGH 
analysis  (Supplementary  Fig.  7e  and  Supplementary  Table  4)  was  corrected  by  the 
method described above. The final product, iPSC-3-G5-A7, had the corrected A1AT, had 
an  intact  genome compared  to  the  parental  fibroblast,  and  expressed  normal  A1AT 
protein when differentiated to hepatocytes (Supplementary Fig. 8 and Supplementary 
Table 4). This is the first demonstration of the generation of mutation-corrected patient-
specific iPSCs, which could realize the therapeutic promise of hIPSCs. 
In  the  present  study,  we  demonstrate  that  ZFNs  and  piggyBac transposon  enable 
simultaneous  bi-allelic  correction  of  diseased  hIPSCs.  No  residual  ectopic  sequences 
remain at the site of correction and the genome appears to be undisturbed elsewhere. 
Although  we  could  readily  obtain  cell  lines  without  large  genomic  alterations  during 
genetic modification, the resulting corrected hIPSCs carry 29 mutations in protein coding 
exons, of which 22 were non-synonymous or splice site mutations. The likely impact of 
this mutation load needs to be considered in the context of their likely functional impact, 
taking  into  account  the  normal  germ-line  load,  accumulated  somatic  variation,  the 
presence of compensating normal gene copies and the requirement for the gene product 
in the derived differentiated cells. From this point of view, only eight mutations might 
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affect  gene  functions  in  hepatocytes  (Supplementary  Table  3).  Nevertheless,  the 
corrected iPSCs could efficiently differentiate to hepatocytes and engraft into the animal 
model for liver injury without tumor formation. Therefore, limited genomic abnormalities 
might  have  restricted  biological  consequences.  Careful  screening  of  primary  and 
corrected hiPSCs using deep sequencing analyses would contribute to the safe use of 
hIPSCs in clinical applications.
Finally,  hIPSCs  derived  from  different  patients  were  effectively  corrected, 
demonstrating that this method could be applied to a large number of A1ATD-hIPSC 
lines.  Since the bi-allelic  correction could be carried out in  less  than 4 months,  our 
approach may be compatible  with large-scale  production of corrected patient-specific 
hIPSCs not only for A1ATD but also for other monogenic disorders.
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Method summary
A1ATD-hIPSCs were described previously15. 2 x 106 hIPSCs were co-transfected with 5 
µg of  each ZFN expression vector  and 2 µg of  the donor  template  and selected in 
puromycin (1 µg/ml) 4 days after transfection. For transposon excision, homozygously 
targeted  cells  were  transfected  with  10  µg  of  pCMV-hyPBase8,  cultured  for  4  days, 
replated  and  selected  in  250  nM  1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-
indouracil (FIAU). To increase clonogenicity, cells were treated with ROCK inhibitor24, Y-
27632 (10 µM) 4 hours prior to dissociation and 24 hours post plating. Resulting colonies 
were  picked  2  weeks  later,  analyzed  by  PCR  and  further  verified  by  Southern  blot 
analysis. 
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Table 1. Summary of gene correction experiments
a Summary of PCR genotyping of ZFN-stimulated gene targeting 
A1ATD-iPSC line
Clones
analyzed Het.a
Homo. /
Hemi. b
Het. +
additional integrations c
Homo. / Hemi. +
additional integrations c Non-targeted d
A 84 45 3 23 8 5
B 18 10 2 3 3 0
C e 216 112 9 52 21 22
Mean frequency [%] 54 6 23 12 5
b Summary of frequencies of bi-allelic piggyBac excision 
Cell line Clones analyzed No. of clones Frequency [%] No. of clones Frequency [%]
B-16 88 15 17 33 38
C-G4 94 5 5 19 20
Mean frequency [%] 11 29
Bi-allelic excision w/o re-integration Bi-allelic excision w/ re-integration
a Het.,  clones  heterozygous  for  PB allele.  b Homo./Hemi.,  clones  homozygous  or 
hemizygous for  PB allele. Cells with one targeted allele and deletion of the other allele 
are undistinguishable from correctly targeted homozygous clones by PCR. Such cells are 
designated as hemizygotes. c Vector backbone integration was analyzed by PCR. d Clones 
showing incorrect PCR bands are included. e A sum of 2 independent experiments.
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Figure Legends
Figure 1. Correction of the G290T mutation in the Tyr gene in mIPSCs. 
a, The strategy for precise genome modification using the piggyBac transposon. Top line, 
structure of the  Tyr gene; red line, 5’ external probe for Southern blot analysis; open 
arrow, piggyBac transposon carrying a PGK-pu∆tk cassette; P1, P2 and P3, primers for 
PCR;  B,  BamHI;  E,  EcoNI.  b,  c,  Southern  blot  (b)  and  PCR  analyses  (c)  showing 
insertion (c/PB) and excision (c/Rev) of the piggyBac transposon in the Tyr gene. mESCs 
(ES) were used as a positive control. d, e, Sequence analyses revealed correction of the 
G290T mutation (d) and seamless excision of the  piggyBac transposon (e). Note that 
two silent mutations (A and T indicated by black arrowheads) introduced near the TTAA 
site by homologous recombination were also detected. f, A chimeric mouse generated by 
injecting corrected Tyr c/Rev mIPSCs (left) displays black coat color, confirming phenotypic 
correction of the albino mutation. Non-injected albino blastocyst was used as a control 
(right). 
Figure 2. Correction of the Z mutation in A1ATD-hIPSCs. 
a,  The  strategy  for  precise  genome  modification  using  ZFNs  and  the  piggyBac 
transposon. Top line, structure of the A1AT gene; blue lines, Southern blot probes; open 
thin and thick boxes, non-cording and cording exons, respectively; open arrow, piggyBac 
transposon; B,  BamHI; A,  AflIII.  b, Sequences of wild-type allele (Reference),  Z allele 
responsible  for  A1ATD,  and  PB allele  carrying  the  piggyBac transposon.  Amino  acid 
position 342 (blue), recognition sites for ZFNs (green), piggyBac excision site (red) are 
shown. Sequence changes in  Rev allele from  Z allele were indicated by asterisks.  c, 
Surveyor nuclease assay showing the cleavage of Z mutation in ZFNs-transfected K562 
cells. Non-transfected cells were used as a control. d, Southern blot analysis showing bi-
allelic piggyBac insertion (B-16) and bi-allelic excision (B-16-C2, B-16-C3 and B-16-C6) 
during correction of the A1ATD-hIPSCs line B. Genomic DNA was digested by BamHI (5’ 
and PB probes) or AlfIII (3’ probe). Genotype are described as follow: ZZ, homozygous 
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for  Z allele; PP, homozygous for insertion of  piggyBac; RR, homozygous for reverted 
allele. e, Sequence analysis showing correction of Z mutation in 3 corrected hIPSC lines. 
Wild-type sequence (top line) and A1ATD-hIPSC (second line). Z point mutation (A) was 
corrected to wild-type sequence (G) while precise  piggyBac excision generated a TTAA 
site, which does not change amino acid sequence. 
Figure 3. Functional analysis of restored A1AT in c-hIPSCs-derived hepatocytes.
a, Immunofluorescence showing the absence of polymeric A1AT protein in hepatocytes 
generated from c-hIPSCs.  All forms of A1AT (left panels) and misfolded polymeric A1AT 
(middle panels).  b, c, ELISA to assess the intracellular (b) and secreted (c) levels of 
polymeric A1AT protein in hepatocytes derived from A1ATD-hIPSCs (ZZ), c-hIPSCs (RR) 
and  control  hIPSCs  (++).  d,  Endoglycosidase  H  (E)  and  peptide:N-glycosidase  (P) 
digestion of A1AT immunoprecipitated from uncorrected (ZZ), corrected (RR) and control 
(++)  hIPSC-derived  hepatocytes  (upper  panels)  and  corresponding  culture  medium 
(lower panels), confirming the absence of A1AT intra-cellular accumulation in corrected 
hIPSCs. e, Chymotrypsin ELISA showing that corrected cells (RR) have A1AT enzymatic 
inhibitory  activity  that  is  superior  to  uncorrected  cells  (ZZ)  and  close  to  adult 
hepatocytes.  f,  ELISA read-out of human albumin in the mouse serum longitudinally 
followed for each mouse. Asterisk, the mouse was subjected to histology analysis. g, h, 
Immunofluorescence of  transplanted liver  sections  detecting human albumin (g)  and 
A1AT (h). DNA was counterstained with DAPI.
Scale bars, 100 µm. Data in b, c and e are shown as mean ± s.d. (n=3). Student’s t-
test was performed. NS, not significant.
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Methods
Plasmid construction
Gateway-adapted piggyBac transposon vectors: A destination vector pPB-R1R2-NP was 
constructed as follows. The attR1 and attR2 sites were PCR-generated and digested by 
NheI/HindIII and XhoI/SpeI, respectively. EM7-neo was PCR-generated and digested by 
HindIII/XhoI. These 3 fragments were then cloned into the NheI-SpeI site of pPB-LR5 25, 
resulting in pPB-R1R2-Neo. An EcoRI-XbaI fragment containing PheS was excised from 
pR6K-R1R2-ZP26, blunt-ended and cloned into the blunted  XhoI site of pPB-R1R2-Neo, 
resulting in pPB-R1R2-NP. An entry vector pENTR-PGKpu∆tk was constructed by cloning 
a KpnI-NotI PGK-pu∆tk fragment into the KpnI-NotI site of pENTR-2B. 
A  targeting  vector  for  Tyr:  The  targeting  vector  was  constructed  using  BAC 
recombineering. A BAC clone RP24-221M7 was introduced into  Escherichia coli strain 
EL350  27. A mini targeting vector was first constructed to modify the  Tyr gene on the 
BAC. Left and right homology arms were PCR-generated and digested by AscI/BsiWI and 
NsiI/PacI,  respectively.  The  transposon  fragment  was  excised  from pPB-R1R2-NP by 
NsiI/BsiWI digestion. These 3 fragments were then cloned into AscI/PacI site of pMCS, 
resulting in pMCS-Tyr-NP.  An  AscI-PacI  fragment was excised from pMSC-Tyr-NP and 
used for BAC targeting. A retrieving vector was constructed by cloning PCR-generated 
left and right homology arm into the XhoI/AscI site of pMSC-DTA, following AscI/HindIII 
and XhoI/HindIII digestion of the left and right arm, respectively. The retrieving vector 
was linearized by HindIII digestion and used to retrieve 3.0-kb 5’ arm, the transposon 
and 6.5-kb 3’  arm. Finally,  the  Neo-PheS cassette was replaced with the  PGK-pu∆tk 
cassette by Gateway cloning, resulting in pDTA-TyrPB. The targeting vector was linearized 
by AscI prior to electroporation into the albino mIPSCs.
A donor template vector for A1AT: A 2-kb fragment, which contained 1 kb at both side of 
Z mutation, was first PCR-amplified using genomic DNA from A1ATD-hIPSC line B as a 
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template and cloned into pCR4-blunt-TOPO (Invitrogen), resulting in pCR4-AAT_Z. To 
construct a donor template with corrected sequence and a piggyBac transposon, the 5’ 
arm  and  3’  arm  were  PCR-amplified  and  digested  with  AscI/NsiI  and  BsiWI/PacI, 
respectively. The  NsiI-BsiWI fragment containing a  piggyBac transposon with the  Neo-
PheS cassette was excised from pPB-R1R2-NP. The digested fragments were cloned into 
the  AscI-PacI site of pMCS, resulting in pMCS-AAT-PB:NP. The  Neo-PheS cassette was 
subsequently replaced with a  PGK-pu∆tk cassette by Gateway cloning, resulting in the 
final donor vector, pMCS-AAT-PB:PGKpu∆tk. 
The plasmids (pPB-R1R2-NP, pENTR-PGKpu∆tk, pMCS-AAT-PB:PGKpu∆tk) are deposited 
in  the  Wellcome  Trust  Sanger  Institute  Archives  and  available  upon  request 
(http://www.sanger.ac.uk/technology/clonerequests/). 
Cell culture
Mouse embryonic fibroblasts (CF1 or B6129F1) were cultured in DMEM containing 10 % 
FCS, 2 mM Glutamine,  0.1 mM 2-melcaptoethanol  and 1x non-essential  amino acid. 
mIPSCs (iPS25∆1; ref.  14) were cultured on MEF-feeder layers in mESC medium: KO-
DMEM supplemented with 15 % FBS, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 1x 
non-essential  amino  acid  and  1000  U/ml  LIF  (Millipore).  A1ATD-hIPSCs  (ref.  15;  A, 
patient 2 line 1; B, patient 1 line1; C, patient 3 line1) were cultured on MEF-feeder 
layers  in  hESC  medium:  DMEM/F12  supplemented  with  20  %  knockout  serum 
replacement, 1 mM GlutaMax, 0.1 mM 2-mercaptoethanol, 1x non-essential amino acid 
and 4 ng/ml FGF2 (Invitrogen). Subculture was performed every 5-7 days by detaching 
hIPSCs by incubation in 0.5 mg/ml dispase and 0.5 mg/ml collagenase type IV for 1 hr 
at  37  °C,  collecting detached hIPSC colonies,  breaking down into  small  clamps and 
plating them onto new feeder plates. 
Gene Targeting and transposon excision in mouse IPSCs
1 x 107 cells were electroporated with 25 µg of a linearized targeting vector in 800 µl of 
HEPES-buffered saline using a Gene Pulser II electroporator (230 V, 500 µF) and plated 
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onto  one-to-three  10-cm  dish.  The  next  day,  puromycin  selection  (1  µg/ml)  was 
initiated.  Resulting colonies were picked and screened by PCR. Targeted clones were 
expanded and further verified by Southern blot analysis. Correctly targeted clones were 
then subjected to transposon excision. 2 x 106 cells were electroporated with 40 µg of 
pCMV-hyPBase in 800 µl of HEPES-buffered saline using a Gene Pulser II electroporator 
(230 V, 500 µF) and plated onto one well of a 6-well plate. After passage once, cells 
were replated on day 4 at 5 x 105 cells per 10-cm dish. On the following day, FIAU (0.2 
µM)  selection  was  initiated.  On  day  5  of  selection,  FIAU  was  withdrawn.  Resulting 
colonies  were  picked  at  day  7  and  screened  by  PCR.  Primer  sequences  to  detect 
homologous recombination are shown in Supplementary Table 2. 
ZFNs-mediated gene targeting in A1ATD-hIPSCs. 
On the day of electropolation (day 0), near-confluent cells were pre-treated with a ROCK 
inhibitor  24 (Y-27632, Sigma) at 10 µM for 3-4 hrs prior to electroporation. Cells were 
then washed with PBS once, detached by Accutase (Millipore; 10 min at 37 °C) and 
mixed  with  DMEM/F12  containing  10%  FCS.  Cells  were  dissociated  into  single-cell 
suspension by vigorous pipetting and counted. 2 x 106 cells were pelleted and mixed 
with 5 µg of a 5’-ZFN expression vector, 5 µg of a 3’-ZFN expression vector and 2 µg of 
the  donor  template  in  100  µl  of  hESC solution  1  (Lonza).  The  cell  suspension was 
transferred to a cuvette and electroporated using the Amaxa Nucleofector device (Lonza) 
with program A23. The electroporated cells were plated onto one or two 10-cm feeder 
dish in MEF-conditioned hESC medium containing 10 µM Y-27632. hESC medium without 
any drug was used for daily medium change between day 1-3. On day 4, puromycin 
selection (1 µg/ml) was started. On day 6, medium was changed to MEF-conditioned 
hESC medium containing 0.5 µg/ml puromycin, which was used for medium change at 
every other day until  picking colonies. Resulting colonies were picked on day 13-17. 
Colonies was cut into 2 pieces. One half was transferred onto a well of 24-well feeder 
plate and the other half was lysed and used for PCR-genotyping. PCR-positive clones 
were further expanded and homologous recombination was verified by Southern blot 
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analysis. 
Transposon excision in homozygously targeted hIPSCs.
Cells were prepared as described above. 2 x 106 cells were mixed with 10 µg of the 
hyperactive piggyBac transposase expression vector (pCMV-hyPBase 8) in 100 µl of hESC 
solution  1  and  electroporated  using  the  Nucleofector  device  with  the  program A23. 
Electroporated cells were plated onto 6-well plate in 1:2, 1:3 and 1:6 dilutions in MEF-
conditioned hESC medium containing 10 µM Y-27632. Note that  ROCK inhibitor  was 
added to the culture medium until day 6 in this experiment. On day 2, cells with ~80 % 
confluency were passaged using Accuate at a split ratio 1:2, 1:3 and 1:6 into 6-well 
plates. On day 4, cells with ~80 % confluency were washed with PBS, detached with 
Accutase, suspended in hESC medium and pelleted. Cells were resuspended in hESC 
medium into single-cell level and counted. 1 x 104 cells were then plated onto one 10-cm 
dish  in  hESC  medium  containing  10  µM  Y-27632.  16-18  hrs  after  plating  (day  5), 
medium was changed to hESC medium containing 0.25 µM FIAU and 10 µM Y-27632. On 
day  6,  medium  was  changed  to  hESC  medium  containing  0.25  µM  FIAU  and  then 
medium  was  changed  every  other  day.  Genotype  and  deletion  of  the  piggyBac 
transposon were analyzed by PCR and further verified by Southern blot analysis. 
CGH analysis
Genomic DNA was extracted using a DNeasy kit (Qiagen). Agilent 244K human genome 
arrays were used following the manufacturer’s protocol. The arrays were scanned with 
an Agilent microarray scanner and data were generated by Agilent Feature Extraction 
software. CGH calls were made with Agilent’s DNA analytics software using the ADM2 
algorithm (6.0 threshold) with a minimum of 5 probes in the region as a filter. 
SNP analysis
An  Illumina  HumanCytoSNP-12  SNP  array  was  used  following  the  manufacturer’s 
protocol. Genotype calls were performed by Illumina’s GenomeStudio. B allele frequency 
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and  log  R  ratio  were  analyzed  by  KaryoStudio.  CNVpatition  v2.4.4  bundled  in 
KaryoStudio was used for copy number analysis. 
ZFN design
ZFNs were designed against a region containing Z mutation in the A1AT gene (see Fig. 
2a, b) and assembled as previously described28. The amino acid residues at positions ‘-1’ 
to ‘+6’ of the recognition alpha helix29,30 of each of the zinc finger DNA-binding domain 
for each DNA triplet target are shown in Supplementary Table 2. The ZFNs were linked to 
wild type  FokI catalytic domain. The activity of the ZFN at the endogenous target site 
was determined using the Surveyor Nuclease assay as previously described31.  
hIPSCs-derived hepatocyte transplantation in immunodeficient uPA transgenic 
mice
Animal  studies  were  conducted  under  protocols  approved  by  the  French  Ministry  of 
Agriculture. Differentiated cells (5 x 105 cells per animal in 50 µl DMEM) were injected 
into the spleens of 3- to 4-week-old Alb-uPA+/+;Rag2-/-;Il2rg-/- mice (n=7). The recipient 
mouse  was  sacrificed  2  weeks  after  transplantation  for  histological  analysis.  Blood 
samples were collected and human albumin in plasma was quantified by ELISA (Bethy 
Laboratories). Frozen liver sections were analyzed by immunofluorecence with human 
albumin (Dako) or human A1AT (Dako) specific antibodies. Non-transplanted mice were 
used as controls.
Exome sequencing
The corrected iPSC line, B-16-C2, and its  parental  fibroblasts  were analyzed.  Exome 
sequencing  and  analysis  were  performed  as  described  previously32 with  minor 
modification.  Exome pulldown was performed using an Agilent SureSelect  Human All 
Exon  50Mb  Kit  according  to  the  manufacturer’s  instructions.  Enriched  DNA  was 
sequenced on Illumina HiSeq2000. 90.32% (Fibroblast-B) and 90.72% (B-16-C2) of total 
targeted regions were covered with more than 10x sequencing depth, covering 93.01% 
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and 93.35% of CCDS exons, respectively.  Substitutions in the coding sequence were 
called as positions with at least 20% of reads reporting a different base with respect the 
reference human sequence (GRCh37). Additionally, somatic mutations were identified by 
comparing  the  sequence  with  the  control  fibroblasts,  and  removing  the  common 
polymorphisms described in dbSNP and in the 1000 Genomes Project33. Small insertions 
and deletions were identified using samtools, as the ones not present in the control cell  
line and that had at least 20x of coverage and 20% of the reads reporting the mutation. 
Validation  of  mutations  was  carried  out  by  Sanger  capillary  sequencing  on  parental 
Fibroblast-B,  A1ATD-hiPSC  line  B,  the  homozygously  targeted  B-16  cells  and  the 
piggyBac-excised B-16-C2 cells.
Sendaiviral regrogramming, RT-PCR, quantitative RT-PCR, bisulfite sequencing, 
immunostaining, flow cytometric analysis, ELISA and EndoH analysis
These experiments were performed as described previously 15,23,34
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